https://novaprd-lb.newcastle.edu.au/vital/access/manager/Index ${session.getAttribute("locale")} 5 DNA methylation profile of triple negative breast cancer-specific genes comparing lymph node positive patients to lymph node negative patients https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:25448 Wed 24 Nov 2021 15:53:38 AEDT ]]> Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013 https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:18998 Wed 20 May 2020 07:08:07 AEST ]]> The expression of Dicer and Drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancer https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:20669 Wed 11 Apr 2018 15:57:11 AEST ]]> Nerve fibers infiltrate the tumor microenvironment and are associated with nerve growth factor production and lymph node invasion in breast cancer https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:27771 In vitro, breast cancer cells were able to induce neurite outgrowth in PC12 cells, and this neurotrophic activity was partially inhibited by anti-NGF blocking antibodies. In conclusion, infiltration by nerve fibers is a feature of the tumor microenvironment that is associated with aggressiveness and involves NGF production by cancer cells. The potential participation of nerve fibers in breast cancer progression needs to be further considered.]]> Wed 11 Apr 2018 11:44:48 AEST ]]> Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:14178 Wed 11 Apr 2018 11:03:59 AEST ]]> Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:22750 Wed 11 Apr 2018 10:56:04 AEST ]]> Novel genes associated with lymph node metastasis in triple negative breast cancer https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:23916 Wed 11 Apr 2018 10:32:03 AEST ]]> Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:8317 Wed 11 Apr 2018 10:31:35 AEST ]]> Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:20763 Wed 11 Apr 2018 09:54:54 AEST ]]> Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:20549 Wed 11 Apr 2018 09:50:48 AEST ]]> Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:19496 Wed 11 Apr 2018 09:40:34 AEST ]]> HER2 status predicts for upfront AI benefit: a TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2 https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:34088 Wed 06 Feb 2019 16:16:15 AEDT ]]> Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): A double-blind, randomised controlled trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:24206 Tue 20 Aug 2024 12:15:13 AEST ]]> Adjuvant ovarian function suppression and cognitive function in women with breast cancer https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:24211 Thu 28 Oct 2021 13:03:31 AEDT ]]> Anastrozole-induced carpal tunnel syndrome: results from the international breast cancer intervention study II prevention trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:23224 Thu 04 Nov 2021 10:40:21 AEDT ]]> Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:24426 Thu 04 Nov 2021 10:39:39 AEDT ]]> Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:23244 Thu 04 Nov 2021 10:39:09 AEDT ]]> Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-Year update of International Breast Cancer Study Group Trial 11-93 https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:7415 Sat 24 Mar 2018 08:40:26 AEDT ]]> Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93 https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:8213 Sat 24 Mar 2018 08:36:20 AEDT ]]> Identifying gaps in the locoregional management of early breast cancer: highlights from the Kyoto Consensus Conference https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:12491 Sat 24 Mar 2018 08:17:12 AEDT ]]> Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:13278 2 twice daily for 14 of every 21 days; n = 107) or continuously (650 mg/m2 twice daily for 21 of every 21 days; n = 107), or to classical CMF (oral cyclophosphamide 100 mg/m2 days 1 to 14 with intravenous methotrexate 40 mg/m2 and fluorouracil 600 mg/m2 on days 1 and 8 every 28 days; n = 109). The primary end point was quality-adjusted progression-free survival (PFS); secondary end points included PFS, overall survival (OS), objective tumor response, and adverse events. Intermittent and continuous capecitabine were to be compared first and, if similar (P > .05), combined for definitive comparisons versus CMF. Results: Quality-adjusted PFS (P = .2), objective tumor response rate (20%; P = .8), and PFS (median, 6 months; hazard ratio [HR], 0.86; 95% CI, 0.67 to 1.10; P = .2) were similar in women assigned capecitabine versus CMF. OS was longer in women assigned capecitabine rather than CMF (median, 22 v 18 months; HR, 0.72; 95% CI, 0.55 to 0.94; P = .02). Febrile neutropenia, infection, stomatitis, and serious adverse events were more common with CMF; hand-foot syndrome was more common with capecitabine. Conclusion: Capecitabine improved OS by being similarly active, less toxic, and more tolerable than CMF. Capecitabine is a good first-line chemotherapy option for women with advanced breast cancer who are unsuited to more intensive regimens.]]> Sat 24 Mar 2018 08:15:16 AEDT ]]> Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:13280 Sat 24 Mar 2018 08:15:16 AEDT ]]> Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:11280 35 kg/m2) at baseline had more recurrences than those women with a low BMI (BMI < 23 kg/m2; adjusted hazard ratio [HR], 1.39; 95% CI, 1.06 to 1.82; Pheterogeneity = .03) and significantly more distant recurrences (adjusted HR, 1.46; 95% CI, 1.07 to 1.61; Pheterogeneity = .01). Overall, the relative benefit of anastrozole versus tamoxifen was nonsignificantly better in thin women compared to overweight women. Conclusion: These results confirm the poorer prognosis of obese women with early-stage breast cancer. Recurrence rates were lower for anastrozole than tamoxifen for all BMI quintiles. Our results suggest that the relative efficacy of anastrozole compared to tamoxifen is greater in thin postmenopausal women and higher doses or more complete inhibitors might be more effective in overweight women, but this requires independent confirmation.]]> Sat 24 Mar 2018 08:12:44 AEDT ]]> Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:11140 Sat 24 Mar 2018 08:10:29 AEDT ]]> Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:17176 Sat 24 Mar 2018 08:06:32 AEDT ]]> Preventive therapy for breast cancer: a consensus statement https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:17172 Sat 24 Mar 2018 08:06:31 AEDT ]]> Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:19000 Sat 24 Mar 2018 08:05:34 AEDT ]]> Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the Breast International Group 1-98 trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:21393 = 30 kg/m²) had slightly poorer OS (hazard ratio [HR] = 1.19; 95% CI, 0.99 to 1.44) than patients with normal BMI (< 25 kg/m²), whereas no trend in OS was observed in overweight (BMI 25 to < 30 kg/m²) versus normal-weight patients (HR = 1.02; 95% CI, 0.86 to 1.20). Treatment-by-BMI interactions were not statistically significant. The HRs for OS comparing obese versus normal BMI were HR = 1.22 (95% CI, 0.93 to 1.60) and HR = 1.18 (95% CI, 0.91 to 1.52) in the letrozole and tamoxifen groups, respectively. Conclusion: There was no evidence that the benefit of letrozole over tamoxifen differed according to patients' BMI.]]> Sat 24 Mar 2018 08:05:04 AEDT ]]> Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the arimidex, tamoxifen alone or in combination trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:17517 Sat 24 Mar 2018 08:03:50 AEDT ]]> Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 Study https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:17404 Sat 24 Mar 2018 08:01:40 AEDT ]]> Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:17734 Sat 24 Mar 2018 07:57:38 AEDT ]]> Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:17782 Sat 24 Mar 2018 07:57:23 AEDT ]]> Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:17755 Sat 24 Mar 2018 07:57:21 AEDT ]]> Recommendations for collection and handling of specimens from group breast cancer clinical trials https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:5271 Sat 24 Mar 2018 07:46:32 AEDT ]]> Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:5363 Sat 24 Mar 2018 07:43:57 AEDT ]]> Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:27579 Sat 24 Mar 2018 07:23:42 AEDT ]]> Reproducibility of visual assessment on mammographic density https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:4920 Sat 24 Mar 2018 07:21:12 AEDT ]]> Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:4862 30 kg/m²) reported more joint symptoms than women with a BMI of 25-30 kg/m² or those with a BMI <25 kg/m² (504 of 1354 women [37·2%] vs 502 of 1926 women [31·3%; OR 1·01 (0·88-1·16)] vs 592 of 1908 women [31·0%; OR 1·32 (1·14-1·53)]) and women on anastrozole reported more joint symptoms compared with those on tamoxifen (949 of 2698 women [35·2%] vs 829 of 2735 women [30·3%]; OR 1·25 [1·11-1·40]). All significant risk factors from the univariate analysis were included in a multivariate analysis and remained significant with little change. Interpretation: In this trial, the major risk factors for developing joint symptoms were previous HRT, hormone-receptor positivity, previous chemotherapy, obesity, and treatment with anastrozole. Discussion of identified risk factors is appropriate when counselling women before initiation of adjuvant hormonal treatment. Funding: This study was funded by Cancer Research UK and AstraZeneca (Macclesfield, UK).]]> Sat 24 Mar 2018 07:18:52 AEDT ]]> Estrogen receptor expression in 21-gene recurrence score predicts increased late recurrence for estrogen-positive/HER2-negative breast cancer https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:22830 interaction = 0.004). Estrogen receptor transcript levels showed inverse prediction across the time windows: HR, 0.88 (0.73–1.07) and 1.19 (0.99–1.43), respectively (Pinteraction = 0.03). Similar time-, module-, and estrogen-dependent relationships were seen for distant recurrence. Conclusions: Patients with tumors with high estrogen receptor transcript levels benefit most from 5 years' endocrine therapy but show increased recurrence rates after 5 years and may benefit from extended therapy. Improved prognostic profiles may be created by considering period of treatment and follow-up time.]]> Sat 24 Mar 2018 07:16:07 AEDT ]]> Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:22087 Sat 24 Mar 2018 07:15:16 AEDT ]]> Exploring decision-making about neo-adjuvant chemotherapy for breast cancer (letter) https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:24782 The Breast Journal.]]> Sat 24 Mar 2018 07:14:06 AEDT ]]> Participant-reported symptoms and their effect on long-term adherence in the International Breast Cancer Intervention Study I (IBIS I) https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:32264 .05). In both treatment arms, we observed significant trends for lower adherence with increasing severity for all symptoms (P < .01) except headaches (P = .054). Conclusion: In the IBIS-I trial, experiencing predefined symptoms in the first 6 months reduced long-term adherence. Effects were similar between treatment arms, suggesting that women were attributing age-related symptoms to preventive therapy. Interventions were required to support symptom management.]]> Mon 23 Sep 2019 11:46:30 AEST ]]> Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015 https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:22889 Annals of Oncology online.]]> Mon 19 Aug 2024 15:42:06 AEST ]]> Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:20880 Mon 11 Mar 2019 12:15:55 AEDT ]]> Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:49499 Fri 19 May 2023 12:01:55 AEST ]]> Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:19871 Fri 16 Aug 2024 15:10:59 AEST ]]> Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of randomised controlled trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:41264 vs 165 cases, hazard ratio [HR] 0·51, 95% CI 0·39–0·66, p<0·0001). The reduction was larger in the first 5 years (35 vsvsvs 70, HR 0·96, 95% CI 0·69–1·34, p=0·82) or for breast cancer (two anastrozole vs three placebo). A significant decrease in non-breast cancers was observed for anastrozole (147 vs 200, odds ratio 0·72, 95% CI 0·57–0·91, p=0·0042), owing primarily to non-melanoma skin cancer. No excess of fractures or cardiovascular disease was observed. Interpretation: This analysis has identified a significant continuing reduction in breast cancer with anastrozole in the post-treatment follow-up period, with no evidence of new late side-effects. Further follow-up is needed to assess the effect on breast cancer mortality.]]> Fri 11 Aug 2023 16:56:23 AEST ]]> Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:5127 Fri 05 Jul 2024 12:28:32 AEST ]]> Treatment adherence and its impact on disease-free survival in the breast international group 1-98 trial of tamoxifen and letrozole, alone and in sequence https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:30333 Fri 01 Apr 2022 09:24:55 AEDT ]]>